AMG National Trust Bank lifted its stake in Chemours Co (NYSE:CC) by 2.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 32,250 shares of the specialty chemicals company’s stock after purchasing an additional 712 shares during the quarter. AMG National Trust Bank’s holdings in Chemours were worth $482,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in the company. Investors Research Corp grew its stake in Chemours by 148.1% during the 2nd quarter. Investors Research Corp now owns 1,206 shares of the specialty chemicals company’s stock valued at $29,000 after purchasing an additional 720 shares during the last quarter. Point72 Hong Kong Ltd purchased a new stake in Chemours during the 2nd quarter valued at about $29,000. Cerebellum GP LLC raised its holdings in Chemours by 107.8% in the 3rd quarter. Cerebellum GP LLC now owns 1,490 shares of the specialty chemicals company’s stock worth $75,000 after purchasing an additional 773 shares during the period. Parallel Advisors LLC raised its holdings in Chemours by 479.4% in the 3rd quarter. Parallel Advisors LLC now owns 2,312 shares of the specialty chemicals company’s stock worth $35,000 after purchasing an additional 1,913 shares during the period. Finally, Quadrant Capital Group LLC raised its holdings in Chemours by 423.4% in the 3rd quarter. Quadrant Capital Group LLC now owns 2,727 shares of the specialty chemicals company’s stock worth $36,000 after purchasing an additional 2,206 shares during the period. Hedge funds and other institutional investors own 76.25% of the company’s stock.
In related news, COO Mark Newman bought 20,000 shares of the business’s stock in a transaction dated Wednesday, September 11th. The shares were acquired at an average price of $16.42 per share, for a total transaction of $328,400.00. Following the purchase, the chief operating officer now owns 114,261 shares in the company, valued at approximately $1,876,165.62. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 2.34% of the company’s stock.
Shares of Chemours stock traded up $0.04 during trading on Wednesday, hitting $15.43. 3,180,322 shares of the company were exchanged, compared to its average volume of 2,565,714. The firm has a 50 day moving average price of $16.91 and a 200 day moving average price of $17.89. The company has a quick ratio of 0.98, a current ratio of 1.72 and a debt-to-equity ratio of 5.05. Chemours Co has a fifty-two week low of $11.71 and a fifty-two week high of $41.60. The stock has a market capitalization of $2.58 billion, a price-to-earnings ratio of 2.72, a P/E/G ratio of 0.42 and a beta of 2.53.
Chemours (NYSE:CC) last issued its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.03. The firm had revenue of $1.39 billion for the quarter, compared to analyst estimates of $1.40 billion. Chemours had a net margin of 7.24% and a return on equity of 58.38%. The firm’s revenue was down 14.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.49 EPS. Analysts predict that Chemours Co will post 2.43 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Friday, November 15th will be paid a $0.25 dividend. The ex-dividend date of this dividend is Thursday, November 14th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 6.48%. Chemours’s dividend payout ratio (DPR) is presently 17.64%.
A number of research firms recently weighed in on CC. Argus cut Chemours from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th. TheStreet lowered Chemours from a “b-” rating to a “c+” rating in a research report on Friday, August 9th. BMO Capital Markets decreased their price target on Chemours from $31.00 to $23.00 and set an “outperform” rating on the stock in a research note on Monday, September 9th. Royal Bank of Canada cut Chemours from an “outperform” rating to a “sector perform” rating and reduced their price objective for the company from $32.00 to $16.00 in a research note on Friday, August 9th. Finally, ValuEngine cut Chemours from a “hold” rating to a “sell” rating in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $26.86.
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.
See Also: Bollinger Bands
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.